MX2015005862A - Enriquecimiento de plasmablastos especificos de antigeno. - Google Patents

Enriquecimiento de plasmablastos especificos de antigeno.

Info

Publication number
MX2015005862A
MX2015005862A MX2015005862A MX2015005862A MX2015005862A MX 2015005862 A MX2015005862 A MX 2015005862A MX 2015005862 A MX2015005862 A MX 2015005862A MX 2015005862 A MX2015005862 A MX 2015005862A MX 2015005862 A MX2015005862 A MX 2015005862A
Authority
MX
Mexico
Prior art keywords
antigen
enrichment
specific plasmablasts
plasmablasts
specific
Prior art date
Application number
MX2015005862A
Other languages
English (en)
Inventor
Henry Chiu
Ning Chai
Zhonghua Lin
Juan Zhang
Mercedesz Balazs
Wyne P Lee
Patrick J Lupardus
Lee R Swen
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2015005862A publication Critical patent/MX2015005862A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4648—Bacterial antigens
    • A61K39/46482—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/464838—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Urology & Nephrology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developmental Biology & Embryology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)

Abstract

La presente invención se refiere a métodos para el enriquecimiento de plasmablastos específicos de antígeno. Los métodos son útiles para la identificación de anticuerpos, incluyendo anticuerpos raros que reconocen más de un antígeno.
MX2015005862A 2012-11-13 2013-11-12 Enriquecimiento de plasmablastos especificos de antigeno. MX2015005862A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725764P 2012-11-13 2012-11-13
PCT/US2013/069588 WO2014078280A1 (en) 2012-11-13 2013-11-12 Enrichment of antigen-specific plasmablasts

Publications (1)

Publication Number Publication Date
MX2015005862A true MX2015005862A (es) 2015-09-10

Family

ID=49640215

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005862A MX2015005862A (es) 2012-11-13 2013-11-12 Enriquecimiento de plasmablastos especificos de antigeno.

Country Status (16)

Country Link
US (1) US20140134638A1 (es)
EP (1) EP2920300B1 (es)
JP (1) JP2015536145A (es)
KR (1) KR20150084831A (es)
CN (1) CN104822828A (es)
AR (1) AR093447A1 (es)
AU (1) AU2013344992A1 (es)
BR (1) BR112015009933A2 (es)
CA (1) CA2889266A1 (es)
HK (1) HK1213009A1 (es)
IL (1) IL238302A0 (es)
MX (1) MX2015005862A (es)
RU (1) RU2015116927A (es)
SG (1) SG11201503706TA (es)
WO (1) WO2014078280A1 (es)
ZA (1) ZA201502711B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190031743A1 (en) 2016-01-29 2019-01-31 Achaogen, Inc. Screening methods for identifying antibodies that bind cell surface epitopes
JP2021521816A (ja) * 2018-04-26 2021-08-30 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 動物の集団内のある動物を追跡する方法およびシステム
WO2023150760A2 (en) * 2022-02-04 2023-08-10 Cornell University Enrichment and characterization of rare circulating cells, including progenitor cells, from peripheral blood, and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993005796A1 (en) * 1991-09-19 1993-04-01 The Scripps Research Institute Method for producing human antibodies in a non-human animal, and animals therefor
US5663481A (en) * 1993-08-06 1997-09-02 Mount Sinai Hospital Corporation Animal model of the human immune system
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
IL118625A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibodies
CA2332336A1 (en) * 1998-05-26 1999-12-02 Erik Depla Method for expanding primate b cells selectively in immunocompromised mice and producing large numbers of antigen-specific b lymphocytes for the production of primate monoclonal antibodies
JP2008526205A (ja) * 2004-12-31 2008-07-24 ジェネンテック・インコーポレーテッド Ｂｒ３に結合するポリペプチド及びその使用
US20070269868A1 (en) * 2006-05-19 2007-11-22 Carvalho Jensen Anne E Culture method for obtaining a clonal population of antigen-specific B cells
US8133727B2 (en) * 2008-11-21 2012-03-13 California Institute Of Technology In vitro human B lymphopoiesis culture system
EP2454283B1 (en) * 2009-07-15 2018-03-14 AIMM Therapeutics B.V. Means and methods for producing high affinity antibodies
EP2703485B1 (en) * 2011-03-30 2018-12-26 National University Corporation University Of Toyama Method for selecting plasma cells and plasmablasts, and method for producing target antigen-specific antibody
GB201212550D0 (en) * 2012-07-13 2012-08-29 Novartis Ag B cell assay

Also Published As

Publication number Publication date
EP2920300A1 (en) 2015-09-23
IL238302A0 (en) 2015-06-30
AU2013344992A1 (en) 2015-05-14
KR20150084831A (ko) 2015-07-22
HK1213009A1 (zh) 2016-06-24
CA2889266A1 (en) 2014-05-22
WO2014078280A1 (en) 2014-05-22
BR112015009933A2 (pt) 2017-12-12
US20140134638A1 (en) 2014-05-15
AR093447A1 (es) 2015-06-10
SG11201503706TA (en) 2015-06-29
EP2920300B1 (en) 2018-09-12
RU2015116927A (ru) 2017-01-10
CN104822828A (zh) 2015-08-05
JP2015536145A (ja) 2015-12-21
ZA201502711B (en) 2016-11-30

Similar Documents

Publication Publication Date Title
MX2022000026A (es) Anticuerpos para tau.
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
PH12014502010A1 (en) Bispecific antibodies against human tweak and human il17 and uses thereof
PH12015501000A1 (en) Anti-notch3 antibodies and antibody-drug conjugates
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
IN2015DN02636A (es)
GB201103836D0 (en) Conjugation process
MX2014002053A (es) Anticuerpos anti -mcsp y metodos de uso.
IN2014DN08481A (es)
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
UA117565C2 (uk) Модифікований олігонуклеотид
UY34582A (es) Anticuerpos anti-cxcr3
NZ705606A (en) Methods for identifying antibodies with reduced immunogenicity
IN2014DN05885A (es)
MX354303B (es) Anticuerpos de anti-biotina y metodos de uso.
MX2014002996A (es) Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
IN2014DN09450A (es)
TW201612191A (en) RSV-specific antibodies and functional parts thereof
IN2013MU00848A (es)
IN2014DN07103A (es)
MX2015005862A (es) Enriquecimiento de plasmablastos especificos de antigeno.
IN2013MU01113A (es)
IN2014DN10209A (es)
EA201691203A1 (ru) Твёрдые формы тенофовира
MY167578A (en) Novel cheese and method for producing the same